Physician

Danxuan Long, MD

According to 2025 Medicare claims, Danxuan Long, MD (NPI: 1205098738) practices pulmonary disease in the Decatur, IL market, with the plurality of this provider's patient population coming from Macon, IL. This provider's primary affiliated billing organization is HSHS MEDICAL GROUP INC (NPI: 1962644807; TIN: 263956318) and primary practice location at 62521-3848. Long is affiliated with the IRCCO (ACO ID: A2619) and HSHS ACO, L.L.C. (ACO ID: A2783), participating under the MSSP model.

Long's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 917 traditional Medicare patients, billed 8,278 HCPCS/CPT codes, and received $321,404 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,259 prescription claims across 563 beneficiaries totaling $1,238,937 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 5,569 claims. Open Payments data shows 41 records totaling $661. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $5,151 to $321,404. Similarly, Part D prescription costs have moved sharply higher in recent years, from $4,040 to $1,238,937. For DME billing, reported payments rose steadily, from $1,066 to $329,168.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	48	53	$5,151
2016	511	1,347	$80,745
2017	496	1,837	$99,977
2018	624	3,499	$183,076
2019	763	4,726	$239,029
2020	838	4,883	$268,765
2021	792	4,760	$291,352
2022	990	5,173	$365,470
2023	902	4,547	$316,140
2024	917	8,278	$321,404

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	12	24	$4,040
2016	130	584	$140,143
2017	184	1,126	$264,784
2018	231	1,604	$450,183
2019	338	2,530	$697,574
2020	373	2,928	$838,696
2021	414	3,501	$1,106,436
2022	484	3,674	$1,226,428
2023	482	3,620	$1,322,964
2024	563	4,259	$1,238,937

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	372	1,422	$152,039
2017	673	3,054	$373,481
2018	927	3,546	$373,713
2019	1,456	5,568	$489,081
2020	1,609	6,084	$654,654
2021	1,667	6,626	$723,870
2022	1,618	5,854	$572,191
2023	1,618	5,512	$507,355
2024	1,722	5,569	$440,040

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	514	1,425	$95
94618	Test for exercise-induced lung stress	334	343	$18
94726	Test to determine lung volumes using sensors	337	339	$9
94060	Test to measure expiratory airflow and volume changes before and after medication administration	314	320	$8
94729	Test to examine how well the lungs exchange gases	343	344	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	727	24,630	$520,958
Fasenra Pen	Benralizumab	15	728	$87,257
Breo Ellipta	Fluticasone/Vilanterol	145	5,550	$72,021
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	94	3,060	$64,669
Spiriva Respimat	Tiotropium Bromide	97	3,060	$50,701

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	12	131	$132,500
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	15	96	$73,111
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	82	572	$47,367
A7030	Full face mask used with positive airway pressure device, each	N	111	233	$22,651
A7031	Face mask interface, replacement for full face mask, each	N	93	220	$22,074

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$661	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Danxuan Long, MD?

Tedicare shows public-source Medicare data for Danxuan Long, MD (NPI 1205098738), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Danxuan Long, MD have ACO affiliation data?

Danxuan Long, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and HSHS ACO, L.L.C. (MSSP, ACO ID A2783).

What billing organization is linked to Danxuan Long, MD?

Danxuan Long, MD is linked to HSHS MEDICAL GROUP INC (billing NPI 1962644807) in the available physician profile data.

Does Danxuan Long, MD have Open Payments data?

Danxuan Long, MD has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.